Clopidogrel
Product Images NDC 60505-3992

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 60505-3992). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ctn300mg30s.jpg (Ctn300mg30s)

Clopidogrel Tablets, USP 300 mg unit-dose tablet packaging label by Apotex Corp. The label shows a box containing 30 tablets in unit-dose packaging with instructions for the pharmacist to dispense the medication guide. It includes the NDC 60505-3532-2 and indicates Rx only, manufactured by Apotex Inc., Toronto, Canada.*

FDA Label Image

Figure3.jpg (Figure3)

A forest plot titled 'Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study' comparing Clopidogrel versus placebo. It shows hazard ratios with confidence intervals across patient subgroups including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke, along with overall outcomes.*

FDA Label Image

Figure3b.jpg (Figure3b)

A forest plot figure depicting hazard ratios for patient baseline characteristics and concomitant medications in the CURE study. It compares outcomes for Clopidogrel versus placebo across subgroups such as Heparin/LMWH, Aspirin dosage, GPIIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use. The x-axis displays hazard ratios with 95% confidence intervals, indicating relative risk favoring Clopidogrel or placebo.*

FDA Label Image

Figure6.jpg (Figure6)

A forest plot chart titled 'Effects of Adding Clopidogrel to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study.' It shows odds ratios with 99% confidence intervals for various subgroups including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, comparing Clopidogrel and placebo effects.*

FDA Label Image

Figure7.jpg (Figure7)

A line graph titled 'Fatal or Non-Fatal Vascular Events in the CAPRIE Study' showing cumulative event rate (%) on the vertical axis and months of follow-up on the horizontal axis. The graph compares event rates over time for Aspirin and Clopidogrel, with Clopidogrel showing a slightly lower cumulative event rate during the follow-up period up to 36 months.*

FDA Label Image

Figure8.jpg (Figure8)

A hazard ratio plot from the CAPRIE study showing 95% confidence intervals for Clopidogrel compared to Aspirin across baseline subgroups including Stroke, MI, PAD, and Overall. The x-axis represents hazard ratios with clustering around the value 1.0, indicating comparative risk levels for these conditions.*

FDA Label Image

Lbl300mg500s.jpg (Lbl300mg500s)

Label for Clopidogrel Tablets, USP 300 mg by Apotex Corp. The label indicates a bottle containing 500 tablets. It shows dosage strength (300 mg), NDC 60505-3532-5, storage instructions, manufacturer locations in Toronto, Ontario, and Weston, Florida, and a barcode. The label instructs pharmacists to dispense the Medication Guide separately.*

FDA Label Image

Lbl75mg30.jpg (Lbl75mg30)

Label for Clopidogrel Tablets, USP 75 mg film-coated tablets in a 30 count package. The label includes usage storage instructions, dosage information, and a barcode. Manufactured by Apotex Inc. and labeled by Apotex Corp.*

FDA Label Image

Clopiodgrel-01.jpg (Clopiodgrel 01)

Chemical structure diagram of Clopidogrel, displaying its molecular composition including carbon, hydrogen, chlorine, sulfur atoms, and a sulfate group (H2SO4).*

FDA Label Image

Figure-01.jpg (Figure 01)

A horizontal bar graph showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of Clopidogrel 75 mg. The graph compares Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with data points and 90% confidence intervals indicating changes relative to Clopidogrel administered alone.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph titled 'Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study' showing cumulative event rates (%) over 12 months of follow-up. Two curves compare placebo plus aspirin versus clopidogrel plus aspirin, with clopidogrel showing a lower event rate throughout. The graph includes a p-value of 0.00009 indicating statistical significance.*

FDA Label Image

Figure4.jpg (Figure4)

A cumulative event rate graph depicting the percentage of deaths before first discharge over days since randomization (up to 28 days) in the COMMIT study. The graph compares placebo and Clopidogrel groups, showing slightly lower deaths in the Clopidogrel group with 7% proportional risk reduction noted.*

FDA Label Image

Figure5.jpg (Figure5)

A line graph titled 'Cumulative Event Rates for the Combined Endpoint Re-Infarction, Stroke or Death in the COMMIT Study' comparing placebo and Clopidogrel groups. The y-axis shows the percentage with death, re-infarction, or stroke before first discharge, ranging from 0 to 11%. The x-axis shows days since randomization up to 28 days. The graph indicates event rates of 10.1% for placebo and 9.2% for Clopidogrel, with a noted 9% proportional risk reduction (p=0.002).*

FDA Label Image

Legacy-75mg-30count.jpg (Legacy 75mg 30count)

Clopidogrel Tablets, USP 75 mg bottle label from Apotex Corp. The label states each tablet contains 75 mg clopidogrel base and provides storage conditions, dispensing instructions, and dosage guidance. It includes the NDC 60505-3992-3, barcode, and manufacturing origin marked as Made in Canada.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.